• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma - Product Image

Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma

  • ID: 2011059
  • December 2011
  • 86 Pages
  • GBI Research

FEATURED COMPANIES

  • Bayer
  • Cubist Pharmaceuticals
  • Pfizer
  • Trius Therapeutics
  • MORE

GBI Research, the leading business intelligence provider, has released its latest research “Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma”. The report provides in-depth analysis of drivers and barriers that impact the global Hospital Acquired Bacterial Infections (HABI) market. The report analyzes the markets for hospital acquired bacterial infections in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The global hospital acquired bacterial infections market mainly comprises of four indications which are Urinary READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer
  • Cubist Pharmaceuticals
  • Pfizer
  • Trius Therapeutics
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Global Hospital Acquired Bacterial Infections Market - Introduction
2.1 GBI Research Report Guidance

3 Global Hospital Acquired Bacterial Infections Market - Market Overview
3.1 Introduction
3.2 Revenue Forecasts for the Global Hospital Acquired Bacterial Infections Market
3.2.1 Sales Value
3.2.2 Annual Cost of Therapy
3.2.3 Treatment Usage Patterns
3.3 Hospital Acquired Bacterial Infections Market Drivers
3.3.1 Increase in Antibacterial Resistance due to Their Frequent Usage
3.3.2 Threat from Emergence of Superbugs
3.4 Hospital Acquired Bacterial Infections Market Restraints
3.4.1 Increased Penetration of Generics Pose as a Threat for Primary Manufacturers
3.4.2 Increased Anti-bacterial Surveillance in Hospitals

4 Global Hospital Acquired Bacterial Infections Market - Therapeutic Landscape
4.1 Hospital Acquired Urinary Tract Infections (UTI) Market
4.1.1 Introduction
4.1.2 Sales Value
4.1.3 Annual Cost of Therapy
4.1.4 Treatment Flow Algorithm
4.1.5 Treatment Usage Patterns
4.1.6 Market Share by Geography
4.2 Hospital Acquired Bacterial Pneumonia (HABP) Market
4.2.1 Introduction
4.2.2 Sales Value
4.2.3 Annual Cost of Therapy
4.2.4 Treatment Flow Algorithm
4.2.5 Treatment Usage Patterns
4.2.6 Market Share by Geography
4.3 Hospital Acquired Bacterial Surgical Site Infections Market
4.3.1 Introduction
4.3.2 Sales Value
4.3.3 Annual Cost of Therapy
4.3.4 Treatment Flow Algorithm
4.3.5 Treatment Usage Patterns
4.3.6 Market Share by Geography
4.4 Hospital Acquired Bacterial Blood Stream Infections (BSI) Market
4.4.1 Introduction
4.4.2 Sales Value
4.4.3 Annual Cost of Therapy
4.4.4 Treatment Flow Algorithm
4.4.5 Treatment Usage Patterns
4.4.6 Market Share by Geography

5 Global Hospital Acquired Bacterial Infections Market - Geographical Landscape
5.1 Geographical Break-up
5.2 The US
5.2.1 Sales Value
5.2.2 Annual Cost of Therapy
5.2.3 Treatment Usage Patterns
5.3 Top Five Countries in Europe
5.3.1 Sales Value
5.3.2 Country Segmentation
5.3.3 Annual Cost of Therapy
5.3.4 Treatment Usage Patterns
5.4 Japan
5.4.1 Sales Value
5.4.2 Annual Cost of Therapy
5.4.3 Treatment Usage Patterns

6 Global Hospital Acquired Bacterial Infections - Pipeline Analysis
6.1 Pipeline Drugs by Phase of Development
6.2 Research and Development Pipeline
6.2.1 Phase III Pipeline Molecules
6.2.2 Phase II Pipeline Molecules
6.2.3 Phase I, Pre-Clinical and Discovery Phase Molecules
6.3 Profiles of Key Late Stage Drugs
6.3.1 Oritavancin
6.3.2 Torezolid
6.3.3 Ceftobiprole Medocaril
6.3.4 Omadacycline/ PTK 0796
6.3.5 Oritavancin

7 Global Hospital Acquired Bacterial Infections Market - Competitive Landscape
7.1 Competitive Profiling
7.1.1 Johnson & Johnson (J&J)
7.1.2 Pfizer
7.1.3 Cubist Pharmaceuticals
7.1.4 Bayer
7.1.5 Trius Therapeutics
7.1.6 Tetraphase Pharmaceuticals Inc.

8 Global Hospital Acquired Bacterial Infections Market - Strategic Consolidations
8.1 Overview
8.2 M&A Deals by Geography
8.3 M&A Deals by Value
8.4 M&A Deals by Deal Type
8.4.1 Merck Completes Acquisition Of Inspire Pharmaceuticals
8.4.2 SciClone Pharmaceuticals Acquires NovaMed Pharmaceuticals
8.4.3 AstraZeneca Completed the Acquisition of Novexel SA in March 2010
8.5 R&D Licensing Agreements
8.5.1 Major Licensing Agreements

9 Global Hospital Acquired Bacterial Infections Market - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Therapeutic Landscape
9.3.5 Market Size by Geography
9.3.6 Geographical Landscape
9.3.7 Pipeline Analysis
9.3.8 Competitive Landscape
9.3.9 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources

1.1 List of Tables
Table 1: Hospital Acquired Bacterial Infections Market, Global, Sales Value ($m), 2002-2010
Table 2: Hospital Acquired Bacterial Infections Market, Global, Sales Value ($m), 2010-2017
Table 3: Hospital Acquired Bacterial Infections Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 4: Hospital Acquired Bacterial Infections Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 5: Hospital Acquired Bacterial Infections Market, Global, Treatment Usage Patterns (million), 2002-2010
Table 6: Hospital Acquired Bacterial Infections Market, Global, Treatment Usage Patterns (million), 2010-2017
Table 7: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Sales Value ($m), 2002-2010
Table 8: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Sales Value ($m), 2010-2017
Table 9: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 10: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 11: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Usage Patterns (million), 2002-2010
Table 12: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Usage Patterns (million), 2010-2017
Table 13: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Geographical Segmentation ($m), 2002-2010
Table 14: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Geographical Segmentation ($m), 2010-2017
Table 15: Hospital Acquired Bacterial Pneumonia Market, Global, Sales Value ($m), 2002-2010
Table 16: Hospital Acquired Bacterial Pneumonia Market, Global, Sales Value ($m), 2010-2017
Table 17: Hospital Acquired Bacterial Pneumonia Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 18: Hospital Acquired Bacterial Pneumonia Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 19: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Usage Patterns (thousand), 2002-2010
Table 20: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Usage Patterns (thousand), 2010-2017
Table 21: Hospital Acquired Bacterial Pneumonia Market, Global, Geographical Segmentation ($m), 2002-2010
Table 22: Hospital Acquired Bacterial Pneumonia Market, Global, Geographical Segmentation ($m), 2010-2017
Table 23: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Sales Value ($m), 2002-2010
Table 24: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Sales Value ($m), 2010-2017
Table 25: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 26: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 27: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Usage Patterns (thousand), 2002-2010
Table 28: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Usage Patterns (thousand), 2010-2017
Table 29: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Geographical Segmentation ($m), 2002-2010
Table 30: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Geographical Segmentation ($m), 2010-2017
Table 31: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Sales Value ($m), 2002-2010
Table 32: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Sales Value ($m), 2010-2017
Table 33: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 34: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 35: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Usage Patterns (thousand), 2002-2010
Table 36: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Usage Patterns (thousand), 2010-2017
Table 37: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Geographical Segmentation ($m), 2002-2010
Table 38: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Geographical Segmentation ($m), 2010-2017
Table 39: Hospital Acquired Bacterial Infections Market, Global, Sales Value by Geography ($m), 2002-2010
Table 40: Hospital Acquired Bacterial Infections Market, Global, Sales Value by Geography ($m), 2010-2017
Table 41: Hospital Acquired Bacterial Infections Market, The US, Sales Value ($m), 2002-2010
Table 42: Hospital Acquired Bacterial Infections Market, The US, Sales Value ($m), 2010-2017
Table 43: Hospital Acquired Bacterial Infections Market, The US, Annual Cost of Therapy ($), 2002-2010
Table 44: Hospital Acquired Bacterial Infections Market, The US, Annual Cost of Therapy ($), 2010-2017
Table 45: Hospital Acquired Bacterial Infections Market, The US, Treatment Usage Patterns (million), 2002-2010
Table 46: Hospital Acquired Bacterial Infections Market, The US, Treatment Usage Patterns (million), 2010-2017
Table 47: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2002-2010
Table 48: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2010-2017
Table 49: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2002-2010
Table 50: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2010-2017
Table 51: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010
Table 52: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017
Table 53: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Treatment Usage Pattern (thousand), 2002-2010
Table 54: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Treatment Usage Pattern (thousand), 2010-2017
Table 55: Hospital Acquired Bacterial Infections Market, Japan, Sales Value ($m), 2002-2010
Table 56: Hospital Acquired Bacterial Infections Market, Japan, Sales Value ($m), 2010-2017
Table 57: Hospital Acquired Bacterial Infections Market, Japan, Annual Cost of Therapy ($), 2002-2010
Table 58: Hospital Acquired Bacterial Infections Market, Japan, Annual Cost of Therapy ($), 2010-2017
Table 59: Hospital Acquired Bacterial Infections Market, Japan, Treatment Usage Pattern (thousand), 2002-2010
Table 60: Hospital Acquired Bacterial Infections Market, Japan, Treatment Usage Pattern (thousand), 2010-2017
Table 61: Hospital Acquired Bacterial Infections Market, Global, Key Pipeline Molecules, Phase III, 2011
Table 62: Hospital Acquired Bacterial Infections Market, Global, Key Pipeline Molecules, Phase II, 2011
Table 63: Hospital Acquired Bacterial Infections Market, Global, Key Pipeline Molecules, Phase I, Discovery, Pre-Clinical, 2011
Table 64: Hospital Acquired Bacterial Infections Market, Global, Major M&A Deals, 2011

1.2 List of Figures
Figure 1: Hospital Acquired Bacterial Infections Market, Global, Drivers and Restraints, 2011
Figure 2: Hospital Acquired Bacterial Infections Market, Global, Sales Value ($m), 2002-2017
Figure 3: Hospital Acquired Bacterial Infections Market, Global, Revenue Segmentation, 2010, 2017
Figure 4: Hospital Acquired Bacterial Infections Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 5: Hospital Acquired Bacterial Infections Market, Global, Therapeutic Usage Patterns (million), 2002-2017
Figure 6: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Sales Value ($m), 2002-2017
Figure 7: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 8: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Flow Algorithm
Figure 9: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Usage Patterns (million), 2002-2017
Figure 10: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Geographical Segmentation ($m), 2002-2017
Figure 11: Hospital Acquired Bacterial Pneumonia Market, Global, Sales Value ($m), 2002-2017
Figure 12: Hospital Acquired Bacterial Pneumonia Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 13: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Flow Algorithm
Figure 14: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Usage Patterns (thousand), 2002-2017
Figure 15: Hospital Acquired Bacterial Pneumonia Market, Global, Market Geographical Segmentation ($m), 2002-2017
Figure 16: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Sales Value ($m), 2002-2017
Figure 17: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 18: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Flow Algorithm
Figure 19: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Usage Patterns (million), 2002-2017
Figure 20: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Geographical Segmentation ($m), 2002-2017
Figure 21: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Sales Value ($m), 2002-2017
Figure 22: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 23: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Flow Algorithm
Figure 24: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Usage Patterns (million), 2002-2017
Figure 25: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Geographical Segmentation ($m), 2002-2017
Figure 26: Hospital Acquired Bacterial Infections Market, Global, Sales Value by Geography ($m), 2002-2017
Figure 27: Hospital Acquired Bacterial Infections Market, The US, Sales Value ($m), 2002-2017
Figure 28: Hospital Acquired Bacterial Infections Market, The US, Annual Cost of Therapy ($), 2002-2017
Figure 29: Hospital Acquired Bacterial Infections Market, The US, Treatment Usage Patterns (million), 2002-2017
Figure 30: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2002-2017
Figure 31: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Sales Value ($m), 2002-2017
Figure 32: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017
Figure 33: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe, Treatment Usage Patterns (thousand), 2002-2017
Figure 34: Hospital Acquired Bacterial Infections Market, Japan, Sales Value ($m), 2002-2017
Figure 35: Hospital Acquired Bacterial Infections Market, Japan, Annual Cost of Therapy ($), 2002-2017
Figure 36: Hospital Acquired Bacterial Infections Market, Japan, Treatment Usage Pattern (thousand), 2002-2017
Figure 37: Hospital Acquired Bacterial Infections, Global, Pipeline by Phase (%), 2010
Figure 38: Hospital Acquired Bacterial Infections Market, Global, SWOT - Johnson & Johnson, 2010
Figure 39: Hospital Acquired Bacterial Infections Market, Global, SWOT - Pfizer, 2010
Figure 40: Hospital Acquired Bacterial Infections Market, Global, SWOT - Cubist, 2010
Figure 41: Hospital Acquired Bacterial Infections Market, Global, SWOT - Bayer, 2010
Figure 42: Hospital Acquired Bacterial Infections Market, Global, M&A Deals by Geography (%), 2004-2011
Figure 43: Hospital Acquired Bacterial Infections Market, Global, M&A Deals by Value (%), 2004-2011
Figure 44: Hospital Acquired Bacterial Infections Market, Global, Major M&A Deals by Deal Type (%), 2004-2011
Figure 45: Hospital Acquired Bacterial Infections Market, Global, Major Licensing Agreements By Geography (%), 2004-2011
Figure 46: Hospital Acquired Bacterial Infections Market, Global, Major Licensing Agreements By Value (%), 2004-2011
Figure 47: GBI Research Market Forecasting Model

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer
  • Cubist Pharmaceuticals
  • Pfizer
  • Trius Therapeutics
  • MORE

GBI Research, the leading business intelligence provider, has released its latest research, “Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma”. It provides in-depth analysis of the drivers and barriers that affect the global Hospital Acquired Bacterial Infections (HABI) market. The report analyzes the markets for HABI in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales and prices are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Hospital Acquired Bacterial Infections (HABI) Market is Expected to Lose $422m Market Value Between 2010 and 2017

The HABI market grew at a Compound Annual Growth Rate (CAGR) of 1.8% from 2002 to 2010 and is forecast to decline at a negative CAGR of 3.7% from 2010 to 2017. The decline in the HABI market in the forecast period will be due to patent expiries of some of the major drugs which are used for hospital acquired bacterial infections and an increase in the hospital surveillance to keep a check on hospital acquired infections. This market nevertheless seems lucrative because premium pricing of novel antibacterials drugs can be achieved. Novel antibacterials will fill the need gap which is currently present in the HABI market. Immuno-compromised patients are more prone to get hospital acquired bacterial infections. It has been observed that patients in the Intensive Care Units (ICUs) get HABI more frequently than those patients who are in the non-ICU wards of the hospital.

Pharmaceutical Companies Prefer Acquisitions to Any Other Deal Type to Penetrate More into the HABI Market

Acquisitions accounted for 89.7% while mergers accounted for 10.3% of the total Merger and Acquisition (M&A) deals. This signifies that from 2004-2011, pharmaceutical companies expanded their presence in the HABI market primarily by acquisitions.

The value of deals is mainly in the range of less than $100m so it is inferred that deals with small and niche companies accounted for a major proportion of all deals that took place in the antibacterials market.

Note: Product cover images may vary from those shown

- "Johnson & Johnson (J&J)
- Pfizer
- Cubist Pharmaceuticals
- Bayer
- Trius Therapeutics
- Tetraphase Pharmaceuticals Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos